ACS Chemical Neuroscience Molecule Spotlight on STX209 (Arbaclofen)

作者：Hopkins Corey R^*

来源：ACS Chemical Neuroscience, 2011, 2(8): 381-381.

DOI：10.1021/cn200061g

• STX209
• autism spectrum disorder (ASD)
• GABA

STX209 (arbaclofen) is a gamma-amino butyric acid type B (GABA(B)) receptor agonist from Seaside Therapeutics currently in clinical trials for autism spectrum disorders (ASD). The company has initiated a phase 2b study after positive results from a phase 2a trial, announced September 2010 (http://www.seasidetherapeutics.com/sites/default/files/STX209_ASD_P2b Trial_Initiation%206%2021%202011%20Final.pdf).

• 出版日期2011-8